Evidence map›Paper›PMID 29979789›Full record

ArticlePloS one2018

BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains.

Mirsada Causevic, Kristina Dominko, Martina Malnar, Lea Vidatic, Stjepko Cermak, Martina Pigoni, Peer-Hendrik Kuhn, Alessio Colombo, Daniel Havas, Stefanie Flunkert and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 5 countries.

Mirsada CausevicLaboratory for Neurodegenerative Disease Research, Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Kristina DominkoLaboratory for Neurodegenerative Disease Research, Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Martina MalnarLaboratory for Neurodegenerative Disease Research, Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Lea VidaticLaboratory for Neurodegenerative Disease Research, Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Stjepko CermakLaboratory for Neurodegenerative Disease Research, Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
Martina PigoniGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Peer-Hendrik KuhnInstitut für Allgemeine Pathologie und pathologische Anatomie, Klinikum rechts der Isar der Technische Universität München and Institute for Advanced Study, Munich, Germany.
Alessio ColomboGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Daniel HavasQPS Austria GmbH, Grambach, Austria.
Stefanie FlunkertQPS Austria GmbH, Grambach, Austria.
Jessica McDonaldThe Ken and Ruth Davee Department of Neurology and Clinical Neurological Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Jenny M GunnersenDepartment of Anatomy and Neuroscience, The University of Melbourne, Parkville, Victoria, Australia.
Birgit Hutter-PaierQPS Austria GmbH, Grambach, Austria.
Sabina TahirovicGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Manfred WindischQPS Austria GmbH, Grambach, Austria.ORCID 0000-0003-1490-7933
Dimitri KraincThe Ken and Ruth Davee Department of Neurology and Clinical Neurological Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Stefan F LichtenthalerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Silva HecimovicLaboratory for Neurodegenerative Disease Research, Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.ORCID 0000-0001-6077-433X
Ruđer Bošković Institute · HRGerman Center for Neurodegenerative Diseases · DEQPS (Austria) · ATNorthwestern University · USThe University of Melbourne · AUTUM Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is intriguing that a rare, inherited lysosomal storage disorder Niemann-Pick type C (NPC) shares similarities with Alzheimer's disease (AD). We have previously reported an enhanced processing of β-amyloid precursor protein (APP) by β-secretase (BACE1), a key enzyme in the pathogenesis of AD, in NPC1-null cells. In this work, we characterized regional and temporal expression and processing of the recently identified BACE1 substrates seizure protein 6 (Sez6) and seizure 6-like protein (Sez6L), and APP, in NPC1-/- (NPC1) and NPC1+/+ (wt) mouse brains. We analysed 4-weeks old brains to detect the earliest changes associated with NPC, and 10-weeks of age to identify changes at terminal disease stage. Sez6 and Sez6L were selected due to their predominant cleavage by BACE1, and their potential role in synaptic function that may contribute to presentation of seizures and/or motor impairments in NPC patients. While an enhanced BACE1-cleavage of all three substrates was detected in NPC1 vs. wt-mouse brains at 4-weeks of age, at 10-weeks increased proteolysis by BACE1 was observed for Sez6L in the cortex, hippocampus and cerebellum of NPC1-mice. Interestingly, both APP and Sez6L were found to be expressed in Purkinje neurons and their immunostaining was lost upon Purkinje cell neurodegeneration in 10-weeks old NPC1 mice. Furthermore, in NPC1- vs. wt-mouse primary cortical neurons, both Sez6 and Sez6L showed increased punctuate staining within the endolysosomal pathway as well as increased Sez6L and BACE1-positive puncta. This indicates that a trafficking defect within the endolysosomal pathway may play a key role in enhanced BACE1-proteolysis in NPC disease. Overall, our findings suggest that enhanced proteolysis by BACE1 could be a part of NPC disease pathogenesis. Understanding the basic biology of BACE1 and the functional impact of cleavage of its substrates is important to better evaluate the therapeutic potential of BACE1 against AD and, possibly, NPC disease.

Indexed as

Amyloid Precursor Protein SecretasesAnimalsAspartic Acid EndopeptidasesBrainDisease Models, AnimalIntracellular Signaling Peptides and ProteinsMice, Inbred BALB CMice, KnockoutNerve Tissue ProteinsNeuronsNiemann-Pick C1 ProteinNiemann-Pick Disease, Type CProteinsProteolysisAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBace1 protein, mouseIntracellular Signaling Peptides and ProteinsNerve Tissue ProteinsNiemann-Pick C1 ProteinNpc1 protein, mouseProteinsSez6 protein, mouse

Identifiers

PMID29979789
PMCPMC6034874
OpenAlexW2817356622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.